Expanding its technology platform with the addition of the Alamar ARGO™ HT System, Allumiqs is strengthening its customer solutions with capabilities in detecting and quantifying proteins at unprecedented levels of sensitivity and accuracy. The ARGO HT System is a fully automated analyzer that uses the unique NULISA™ technology to enable high-throughput, ultra-sensitive proteomic analysis, driving new discoveries in disease biomarkers, particularly in neuroscience and oncology.

“We believe in the combined power of technology and omics expertise. The addition of the ARGO HT System further optimizes our solutions and provides an exciting opportunity to expand our customer collaborations in critical areas of neurodegenerative research including Alzheimer’s and Parkinson’s diseases,” Derek Gooderham, Chief Commercial Officer, Allumiqs.

Allumiqs is committed to listening to customer needs and evolving its solutions platform with the latest technologies, such as Alamar’s ARGO HT System for protein biomarker profiling, drug development, and precision medicine. This strategic investment and the broader collaboration with Alamar ensure that Allumiqs continues to evolve its multiomics and data-driven drug development solutions for customers.

With its automated workflow, the ARGO HT System significantly reduces hands-on time, allowing for the efficient and streamlined analysis of large sample cohorts. Its ability to perform single-plex assays in under 8 hours and multiplex assays in less than 15 hours accelerates biomarker validation and clinical translation.

Key benefits of the ARGO HT System in combination with NULISA include:

• Profiling 1-100s of protein biomarkers from biofluid samples
• Unprecedented attomolar level sensitivity (fg/mL) spanning 12+ logs dynamic range
• Minimal input required (25uL) from precious research sample

Learn more about the ARGO HT System and the Allumiqs Technology Platform